Annweiler C, Rolland Y, Schott AM, Blain H, Vellas B, Beauchet O Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study. Dement Geriatr Cogn Disord. 2011;32(4):273-8. doi: 10.1159/000334944. Epub 2012 Jan 19.
Bartali B, Devore E, Grodstein F, Kang JH Plasma vitamin D levels and cognitive function in aging women: the nurses' health study. J Nutr Health Aging. 2014 Apr;18(4):400-6. doi: 10.1007/s12603-013-0409-9.
Berridge MJ Vitamin D cell signalling in health and disease. Biochem Biophys Res Commun. 2015 Apr 24;460(1):53-71. doi: 10.1016/j.bbrc.2015.01.008. Review.
Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014 Jun 24;14:643. doi: 10.1186/1471-2458-14-643. Review.
Etgen T, Sander D, Bickel H, Sander K, Förstl H Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement Geriatr Cogn Disord. 2012;33(5):297-305. doi: 10.1159/000339702. Epub 2012 Jul 2. Review.
Evans MK, Lepkowski JM, Powe NR, LaVeist T, Kuczmarski MF, Zonderman AB Healthy aging in neighborhoods of diversity across the life span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status. Ethn Dis. 2010 Summer;20(3):267-75.
Eyles DW, Burne TH, McGrath JJ Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013 Jan;34(1):47-64. doi: 10.1016/j.yfrne.2012.07.001. Epub 2012 Jul 11. Review.
Ibrahim JG, Molenberghs G Missing data methods in longitudinal studies: a review. Test (Madr). 2009 May 1;18(1):1-43.
Llewellyn DJ, Lang IA, Langa KM, Melzer D Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):59-65. doi: 10.1093/gerona/glq185. Epub 2010 Nov 1.
Llewellyn DJ, Langa KM, Lang IA Serum 25-hydroxyvitamin D concentration and cognitive impairment. J Geriatr Psychiatry Neurol. 2009 Sep;22(3):188-95. doi: 10.1177/0891988708327888. Epub 2008 Dec 10.
Maddock J, Cavadino A, Power C, Hyppönen E 25-hydroxyvitamin D, APOE ?4 genotype and cognitive function: findings from the 1958 British birth cohort. Eur J Clin Nutr. 2015 Apr;69(4):505-8. doi: 10.1038/ejcn.2014.201. Epub 2014 Oct 8.
Maddock J, Geoffroy MC, Power C, Hyppönen E 25-Hydroxyvitamin D and cognitive performance in mid-life. Br J Nutr. 2014 Mar 14;111(5):904-14. doi: 10.1017/S0007114513003176. Epub 2013 Oct 18.
McCann JC, Ames BN Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J. 2008 Apr;22(4):982-1001. Epub 2007 Dec 4. Review.
Miller JW Vitamin D and cognitive function in older adults: are we concerned about vitamin D-mentia? Neurology. 2010 Jan 5;74(1):13-5. doi: 10.1212/WNL.0b013e3181c719a2. Epub 2009 Nov 25.
Moon JH, Lim S, Han JW, Kim KM, Choi SH, Kim KW, Jang HC Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin Endocrinol (Oxf). 2015 Jul;83(1):36-42. doi: 10.1111/cen.12733. Epub 2015 Mar 4.
Perna L, Mons U, Kliegel M, Brenner H Serum 25-hydroxyvitamin D and cognitive decline: a longitudinal study among non-demented older adults. Dement Geriatr Cogn Disord. 2014;38(3-4):254-63. doi: 10.1159/000362870. Epub 2014 Jun 25.
Przybelski RJ, Binkley NC Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem Biophys. 2007 Apr 15;460(2):202-5. Epub 2007 Jan 8.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.